ライフサイエンスコーパス: severe combined

1 The recessive mutant scat (severe combined anemia and thrombocytopenia) alternates

2 ssays, flow cytometry, and nonobese diabetic/severe combined immune deficienct mouse transplantation.

3 erapy (GT) for adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID) can provide

4 mmune disorders in human subjects, including severe combined immune deficiency (biallelic null mutati

5 lting in primary immune deficiencies such as severe combined immune deficiency (SCID) and X-linked ag

6 with diverse clinical phenotypes, including severe combined immune deficiency (SCID), autoimmunity,

7 immune deficiency diseases (PIDs), including severe combined immune deficiency (SCID), Wiskott-Aldric

8 a and result in the clinical presentation of severe combined immune deficiency (SCID).

9 splantation (HSCT) for infants with X-linked severe combined immune deficiency (SCID-X1) lacking a ma

10 liver urokinase-type plasminogen activator, severe combined immune deficiency (uPA-SCID) mice" (chim

11 d Rag1-F971L mice, which represent models of severe combined immune deficiency and combined immune de

12 re combined immunodeficiency (SCID) known as severe combined immune deficiency caused by adenosine de

13 For many years, severe combined immune deficiency diseases, which are ch

14 une cell reconstitution in nonobese diabetic severe combined immune deficiency gamma-/- mice reconsti

15 otoxic mechanisms in mice homozygous for the severe combined immune deficiency mutation in the protei

16 in upper airway samples from an infant with severe combined immune deficiency syndrome and persisten

17 mary immunodeficiency, ranging from T(-)B(-) severe combined immune deficiency to delayed-onset disea

18 ities in thrombus formation in patients with severe combined immune deficiency, Glanzmann's thrombast

19 atments for several PIDs, including forms of severe combined immune deficiency, Wiskott-Aldrich syndr

20 erved in the metastatic lung cancer model in Severe Combined Immune Deficiency-beige (SCID-bg) mice,

21 ried with male children given a diagnosis of severe combined immune deficiency.

22 mol of Tyr(4)-BBN: in vivo GRPR blockade) in severe combined immune deficient mice bearing PC-3 xenog

23 rus type 1 infection were tested in nonobese severe combined immune-deficient mice reconstituted with

24 In severe combined immune-deficient mice, overexpression of

25 that overexpress miR-26a or its inhibitor in severe combined immune-deficient mice.

26 ted into peri-infarct areas of the hearts of severe combined immune-deficient mice.

27 burnetii infection-induced diseases in both severe combined immunity-deficient (SCID) and muMT mice

28 A subgroup of severe combined immunodeficiencies (SCID) is characteriz

29 affected with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out

30 c contrast, 39 adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients hav

31 'difficult' conditions [adenosine deaminase-severe combined immunodeficiency (ADA-SCID), major histo

32 ites that destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often refer

33 Although its complete defect causes severe combined immunodeficiency (ie, T(-)B(-) severe co

34 oss of T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome

35 l CD34(+) progenitors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulte

36 A-overexpressing tumors in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with pa

37 (STZ)-induced diabetes in nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice.

38 and nail dystrophy, accounting for the nude/severe combined immunodeficiency (nu/SCID) phenotype in

39 telangiectasia and a class of Radiosensitive-Severe Combined Immunodeficiency (RS-SCID), respectively

40 function therefore results in radiosensitive severe combined immunodeficiency (RS-SCID).

41 function of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many

42 with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular rad

43 oietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primar

44 Population-based newborn screening for severe combined immunodeficiency (SCID) and related diso

45 Severe combined immunodeficiency (SCID) and X-linked aga

46 Severe combined immunodeficiency (SCID) arises from diff

47 Severe combined immunodeficiency (SCID) can be cured by

48 018), we show that over 90% of patients with severe combined immunodeficiency (SCID) can be genetical

49 Severe combined immunodeficiency (SCID) carries a poor p

50 tivating gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a comp

51 Severe combined immunodeficiency (SCID) comprises a grou

52 Severe combined immunodeficiency (SCID) comprises a hete

53 to the pathology of Omenn syndrome and leaky severe combined immunodeficiency (SCID) has not been pre

54 The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide

55 in reticular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans.

56 Severe combined immunodeficiency (SCID) is a life-threat

57 Early recognition of severe combined immunodeficiency (SCID) is a pediatric e

58 Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by gen

59 Severe combined immunodeficiency (SCID) is characterized

60 Severe combined immunodeficiency (SCID) is characterized

61 adenosine deaminase (ADA) cause a subtype of severe combined immunodeficiency (SCID) known as severe

62 MA I&T was determined in LNCaP tumor-bearing severe combined immunodeficiency (SCID) mice after sacri

63 verexpressing SDF-1alpha were xenografted on severe combined immunodeficiency (SCID) mice.

64 tiated by transfer of their splenocytes into severe combined immunodeficiency (SCID) mice.

65 ed autophagy in human skin xenografts in the severe combined immunodeficiency (SCID) mouse model of V

66 me for at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft

67 se of nonobese diabetic (NOD) mice, NOD with severe combined immunodeficiency (scid) mutation (SCID)

68 fetal liver cells in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) or NOD/SCID/gamm

69 ic and nonimmunologic outcomes in cohorts of severe combined immunodeficiency (SCID) patients with ei

70 Severe combined immunodeficiency (SCID) represents conge

71 Severe combined immunodeficiency (SCID) represents the m

72 dysgenesis is an autosomal recessive form of severe combined immunodeficiency (SCID) that usually man

73 onsortium (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective

74 Newborn screening for severe combined immunodeficiency (SCID) using assays to

75 Severe combined immunodeficiency (SCID) with a complete

76 the 91 position found in some patients with severe combined immunodeficiency (SCID), and the double

77 d T-cell reconstitution in many infants with severe combined immunodeficiency (SCID), but correction

78 have been identified, often associated with severe combined immunodeficiency (SCID), consistent with

79 of typical profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefu

80 the cervical spinal cords of adult mice with severe combined immunodeficiency (SCID), human pluripote

81 cell transplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survi

82 hly relevant per se because in patients with severe combined immunodeficiency (SCID), infections caus

83 minase (ADA) deficiency, a cause of X-linked severe combined immunodeficiency (SCID), is a case in po

84 t profound primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in inf

85 The most severe form, severe combined immunodeficiency (SCID), presents with p

86 the natural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich

87 abrogate lymphocyte development and lead to severe combined immunodeficiency (SCID), XLF mutations c

88 tations in ORAI1 or STIM1 genes present with severe combined immunodeficiency (SCID)-like disease.

89 T-cell development, clinically presenting as severe combined immunodeficiency (SCID).

90 repair pathway result in radiation-sensitive severe combined immunodeficiency (SCID).

91 nt of Babesia microti infection in mice with severe combined immunodeficiency (SCID).

92 ion (DRG) xenografts maintained in mice with severe combined immunodeficiency (SCID).

93 population-based newborn screening (NBS) for severe combined immunodeficiency (SCID).

94 (HCT) of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

95 recombination, hence loss of DNA-PK leads to severe combined immunodeficiency (SCID).

96 g immune plasma in young horses (foals) with severe combined immunodeficiency (SCID).

97 in a significant proportion of patients with severe combined immunodeficiency (SCID).

98 cell transplantation (HSCT) in patients with severe combined immunodeficiency (SCID).

99 erleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

100 systemic metabolic disease characterized by severe combined immunodeficiency (SCID).

101 scribe the generation of a marmoset model of severe combined immunodeficiency (SCID).

102 e T- or B-lymphocytes and are diagnosed with severe combined immunodeficiency (SCID).

103 ls (1 Arabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID).

104 cured immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1) and adenine d

105 X-linked severe combined immunodeficiency (SCID-X1) caused by mut

106 X-linked Severe Combined Immunodeficiency (SCID-X1) is a genetic

107 ietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails t

108 ical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney mu

109 vector for the correction of canine X-linked severe combined immunodeficiency (SCID-X1).

110 m healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1).

111 growth in vivo in hairless outbred mice with severe combined immunodeficiency (SHO-Prkdc(scid)Hr(hr))

112 X-linked severe combined immunodeficiency (X-SCID) is an immune d

113 clinical case of an RSV-infected infant with severe combined immunodeficiency and effectively no adap

114 Mutations associated with severe combined immunodeficiency and Omenn syndrome had

115 g its goal of defining the true incidence of severe combined immunodeficiency and providing early tre

116 primary immunodeficiencies (PIDs) including severe combined immunodeficiency and Wiskott-Aldrich syn

117 Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimm

118 g in California established the incidence of severe combined immunodeficiency at 1 in 66,250 live bir

119 raftment is a common finding in infants with severe combined immunodeficiency but is not typically ob

120 correct T-cell deficiencies in patients with severe combined immunodeficiency by replacing resident t

121 delivered via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in

122 eficiency CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of

123 Severe combined immunodeficiency can be caused by loss-o

124 ells has emerged as a convincing therapy for severe combined immunodeficiency caused by ILR2G mutatio

125 chain cytokine receptor subunit give rise to severe combined immunodeficiency characterized by lack o

126 Norovirus incidence was compared between severe combined immunodeficiency children with (n = 10)

127 Further, the nonobese diabetic severe combined immunodeficiency common gamma chain knoc

128 Newborn screening for severe combined immunodeficiency detects athymic patient

129 marked decrease in survival and developed a severe combined immunodeficiency disease (SCID) affectin

130 The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and rela

131 wn to lead to an autosomal recessive form of severe combined immunodeficiency disease (SCID).

132 PET experiments were performed in severe combined immunodeficiency disease mice inoculated

133 Patients with severe combined immunodeficiency disease who have matche

134 ications of anti-CD3epsilon mAb treatment in severe combined immunodeficiency forms characterized by

135 r from healthy donors were injected into NOD-severe combined immunodeficiency gammac(-/-) mice, follo

136 and patients with atypical presentations of severe combined immunodeficiency gene mutations presents

137 patients with adenosine deaminase deficient severe combined immunodeficiency have identified neutrop

138 homing, and engraftment in nonobese diabetic/severe combined immunodeficiency IL-2gamma(null) (NSG) m

139 In 6.5 years of newborn screening for severe combined immunodeficiency in California, 3,252,15

140 e gene encoding gamma(c) results in X-linked severe combined immunodeficiency in humans, and gamma(c)

141 ndent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05).

142 lial cells, leading to increased survival of severe combined immunodeficiency mice after transplantat

143 n vivo after subcutaneous transplantation in severe combined immunodeficiency mice and differentiated

144 umab and copper-DOTA-conatumumab was done in severe combined immunodeficiency mice bearing Colo205 xe

145 In female CB17 severe combined immunodeficiency mice bearing Colo205 xe

146 ession by PET and ex vivo biodistribution in severe combined immunodeficiency mice bearing H2009 tumo

147 in vivo experiments, 6- to 12-wk-old female severe combined immunodeficiency mice bearing M21 xenogr

148 ol Tyr(4)-BBN: for in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenog

149 LL cells transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapit

150 Finally, YT cells transplanted into severe combined immunodeficiency mice had an invasive be

151 Six nonobese diabetic severe combined immunodeficiency mice received transplan

152 uppressed the development of diabetes in NOD severe combined immunodeficiency mice receiving diabetog

153 tumor transplantation in Non-obese diabetic/severe combined immunodeficiency mice that the HAGE knoc

154 ansplanted nonobese diabetic background with severe combined immunodeficiency mice to assess suppress

155 Nonobese diabetic/severe combined immunodeficiency mice transplanted with

156 The tumorigenicity of cells in severe combined immunodeficiency mice was augmented to a

157 Male severe combined immunodeficiency mice were subcutaneousl

158 Humanized urokinase plasminogen activator/severe combined immunodeficiency mice were used to estab

159 nd decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with P

160 EB-silenced MM cells were then injected into severe combined immunodeficiency mice, and tumor growth

161 In a xenograft analysis of severe combined immunodeficiency mice, cisplatin also ef

162 MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the im

163 In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of hu

164 esis in immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an onc

165 ibroblasts and in aggressive tumor growth in severe combined immunodeficiency mice.

166 lanted subcutaneously into nonobese diabetic severe combined immunodeficiency mice.

167 he same day prior to graft implantation into severe combined immunodeficiency mice.

168 ppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice.

169 antly inhibited cholangiocarcinoma growth in severe combined immunodeficiency mice.

170 in vitro and in engrafted nonobese diabetic-severe combined immunodeficiency mice.

171 ted in the choroids of six nude rats and six severe combined immunodeficiency mice.

172 otype when transplanted to nonobese diabetic/severe combined immunodeficiency mice.

173 tive transfer, delayed diabetes onset in NOD.severe combined immunodeficiency mice.

174 presses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice.

175 in human PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice.

176 d into the skeletal muscle of dystrophic mdx/severe combined immunodeficiency mice.

177 g soft agar assays and xenograft analysis of severe combined immunodeficiency mice.

178 ive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

179 ing CD-1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

180 ro, and suppressed tumor xenograft growth in severe combined immunodeficiency mice.

181 nsplantation into diabetic nonobese diabetic-severe combined immunodeficiency mouse kidneys.

182 nd virulence in human skin xenografts in the severe combined immunodeficiency mouse model in vivo.

183 tensively in infected skin xenografts in the severe combined immunodeficiency mouse model of VZV path

184 Using a nonobese diabetic/severe combined immunodeficiency mouse model, those anti

185 tem with experimental systemic infections of severe combined immunodeficiency Mus musculus with the b

186 tuted with a synthetic LAT gene bearing this severe combined immunodeficiency mutation.

187 ency causes T(-)B(+) natural killer-positive severe combined immunodeficiency or T-cell lymphopenia w

188 h overexpression of Bcl2 does not rescue the severe combined immunodeficiency phenotype in Ku70-defic

189 We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T

190 A 14-year-old boy with severe combined immunodeficiency presented three times t

191 - and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from dissemin

192 ell lymphopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block

193 chronic inflammation, muscle weakness, and a severe combined immunodeficiency syndrome.

194 , with a spectrum of phenotypes ranging from severe combined immunodeficiency to immune dysregulation

195 We performed a multicenter survey of severe combined immunodeficiency transplantation centers

196 nts with adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly differ

197 ere identified through newborn screening for severe combined immunodeficiency using the T-cell recept

198 ariants in AK2 cause reticular dysgenesis, a severe combined immunodeficiency with agranulocytosis, l

199 SCID (severe combined immunodeficiency) mice underwent left an

200 When xenografted into SCID (severe combined immunodeficiency) mice, the expression o

201 vere combined immunodeficiency (ie, T(-)B(-) severe combined immunodeficiency), its suboptimal activi

202 ype per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice.

203 kidney capsules of SCID mice (ie, mice with severe combined immunodeficiency).

204 ons in Orai1 Ca2+ channels lead to a form of severe combined immunodeficiency, auto-immunity, muscle

205 ions in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 d

206 ete recovery occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type m

207 orrection of disease phenotypes for X-linked severe combined immunodeficiency, chronic granulomatous

208 d adults with specific forms of PID, such as severe combined immunodeficiency, for over 10 years.

209 treatment advances and newborn screening for severe combined immunodeficiency, has resulted in improv

210 gene replacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Ama

211 ere divided into 3 main categories: T(-)B(-) severe combined immunodeficiency, Omenn syndrome, and co

212 mmune system since it did not occur in nude, severe combined immunodeficiency, or T-cell depleted mic

213 is with neutrophil infiltration in mice with severe combined immunodeficiency, which is accompanied b

214 ndergone bone marrow transplant for X-linked severe combined immunodeficiency, with no recovery of T

215 ) were given intranasally or i.p. to newborn severe combined immunodeficiency-beige mice exposed to 9

216 yptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the par

217 Nonobese diabetic-severe combined immunodeficiency-gammac(-/-) mice were i

218 th and prevented bone destruction in vivo in severe combined immunodeficiency-hu mice.

219 rchy contains a rare CD34(-) population with severe combined immunodeficiency-repopulating capacity.

220 ly, such protection occurred without causing severe combined immunodeficiency.

221 ally attenuated MM tumor growth in mice with severe combined immunodeficiency.

222 benefits with gene therapy for ADA-deficient severe combined immunodeficiency.

223 ng Tgfb1-null mutant mice on a background of severe combined immunodeficiency.

224 in Matrigel, and formed tumors in mice with severe combined immunodeficiency.

225 ratoma assays in nonobese diabetic mice with severe combined immunodeficiency.

226 c), which is mutated in humans with X-linked severe combined immunodeficiency.

227 in humans and null mutations in mice lead to severe combined immunodeficiency.

228 y CLL cells proliferate in nonobese diabetes/severe combined immunodeficiency/gammac(null) mice under

229 geneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rgamma(nul

230 nstitute immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gammac re

231 Therefore, we created a nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

232 Human fetal lung tissue was implanted into severe combined immunodeficient (CB17-scid) mice and ino

233 higher tumor incidence in nonobese diabetic/severe combined immunodeficient (NOD/SCID) Ilgamma2(null

234 imaging were done on male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice bearing

235 n the peritoneal cavity of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

236 regression was blocked in nonobese diabetic/severe combined immunodeficient (NOD/SCID-gamma) mice, w

237 titumor effects of MEDI-575 in tumor-bearing severe combined immunodeficient (SCID) mice and in genet

238 in the brain's extracellular space of C.B.17 severe combined immunodeficient (scid) mice and tumor ce

239 Severe combined immunodeficient (SCID) mice carry a germ

240 iver homogenates after 24 serial passages in severe combined immunodeficient (SCID) mice caused sever

241 vivo binding characteristics were studied in severe combined immunodeficient (SCID) mice inoculated w

242 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice to induce IT

243 Severe combined immunodeficient (SCID) mice were infecte

244 WT) mice were subjected to DNFB-induced CHS, severe combined immunodeficient (SCID) mice were injecte

245 Inoculation of severe combined immunodeficient (SCID) mice yielded isol

246 When implanted subcutaneously in severe combined immunodeficient (SCID) mice, MDA-PCa-118

247 AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting

248 or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mice.

249 ll as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice.

250 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice.

251 RAG1-mutants from severe combined immunodeficient (SCID) patient cells sho

252 wn in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobes

253 In liver-humanized uPA/severe combined immunodeficient (SCID)/beige mice challe

254 and after transplantation into the livers of severe combined immunodeficient (SCID)/beige mice.

255 g plasmablasts can be enriched in vivo, in a severe combined immunodeficient (SCID)/beige mouse host.

256 erposition graft in the abdominal aorta of a severe combined immunodeficient Beige mouse model suppor

257 Humanized nonobese diabetic severe combined immunodeficient common gamma chain-defic

258 s to restore euglycemia in nonobese diabetic/severe combined immunodeficient diabetic recipients was

259 Nonobese diabetic severe combined immunodeficient gammac(-/-) (NSG) mice r

260 In contrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, h

261 In severe combined immunodeficient mice bearing SKOV3 tumor

262 PET/CT small-animal imaging was performed in severe combined immunodeficient mice bearing solid and d

263 Severe combined immunodeficient mice bearing uveal melan

264 An in vivo efficacy trial with severe combined immunodeficient mice implanted with subc

265 5(+) T cells to infected macrophage-depleted severe combined immunodeficient mice induced CNS demyeli

266 Nonobese diabetic severe combined immunodeficient mice lacking the cytokin

267 t VEGF111 addition before transplantation to severe combined immunodeficient mice ovaries.

268 Female severe combined immunodeficient mice were fed a low-fat/

269 Severe combined immunodeficient mice were given injectio

270 M21 (human melanoma)-bearing severe combined immunodeficient mice were used for biodi

271 inst subcutaneous B-cell tumor xenografts in severe combined immunodeficient mice with comparable or

272 HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopul

273 Severe combined immunodeficient mice xenografted with M2

274 volume, rate of metastasis, and mortality of severe combined immunodeficient mice xenografted with PC

275 ondii in BALB/c mice, immunocompetent, or in severe combined immunodeficient mice, and after treatmen

276 neither resulted in weight loss nor death in severe combined immunodeficient mice, and pock lesions w

277 In severe combined immunodeficient mice, the antitumor effi

278 sicles in a model of glycerol-induced AKI in severe combined immunodeficient mice.

279 -reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice.

280 n into the left subrenal capsule of diabetic severe combined immunodeficient mice.

281 ression was studied in nonobese diabetic and severe combined immunodeficient mice.

282 we implanted human-derived glioma cells into severe combined immunodeficient mice.

283 ibited human CCA cell growth in vitro and in severe combined immunodeficient mice.

284 asion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor gr

285 cells, using a xenogeneic nonobese diabetic/severe combined immunodeficient mouse model.

286 inant hepatic failure in a nonobese diabetic severe combined immunodeficient mouse model.

287 edium before transfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.

288 an CD19(+) tumors in immunocompromised SCID (severe combined immunodeficient)-Beige mice.

289 (PMNs) and in human intestinal xenografts in severe-combined immunodeficient (SCID-HU-INT) mice, a no

290 owth of malignant mesothelioma xenografts in severe-combined immunodeficient mice and extended host s

291 cells were injected intratibially in C3H and severe-combined immunodeficient mice.

292 C1 was seen toward H460 tumor xenografts in severe-combined immunodeficient mice.

293 um antibodies to the systemic compartment of severe-combined-immunodeficient (SCID) mice temporarily

294 line (EGI-1) after xenotransplantation into severe-combined-immunodeficient mice, (3) expression of

295 ilator dependent and, where tested, revealed severe combined mitochondrial respiratory chain deficien

296 outcome (preterm delivery, NICU, SGA); and "severe" combined outcome (early preterm delivery, NICU,

297 eral" combined outcome, 34.1% versus 90.0%; "severe" combined outcome, 21.4% versus 80.0%; P<0.001).

298 nation (p.Val255Ile and p.Arg282Pro) and the severe combined phenotype (p.Asn414Lys) resulted in norm

299 for H-ABC (p.Asp249Asn), DYT4 (p.Arg2Gly), a severe combined phenotype with hypomyelination and encep

300 xidase deficiency in all patients tested and severe, combined respiratory chain complex activity defi